Business Description
Vaxcyte Inc
NAICS : 541713
SIC : 2834
ISIN : US92243G1085
Share Class Description:
PCVX: Ordinary SharesDescription
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 56.79 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -10.7 | |||||
| 3-Year EPS without NRI Growth Rate | -4.4 | |||||
| 3-Year FCF Growth Rate | -32.4 | |||||
| 3-Year Book Growth Rate | 24.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -12.99 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.82 | |||||
| 9-Day RSI | 41.33 | |||||
| 14-Day RSI | 51.12 | |||||
| 6-1 Month Momentum % | 74.37 | |||||
| 12-1 Month Momentum % | 128.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.88 | |||||
| Quick Ratio | 17.88 | |||||
| Cash Ratio | 17.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.1 | |||||
| Shareholder Yield % | -7.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.89 | |||||
| ROA % | -28.96 | |||||
| ROIC % | -128.16 | |||||
| 3-Year ROIIC % | -92.38 | |||||
| ROC (Joel Greenblatt) % | -475.57 | |||||
| ROCE % | -33.26 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 6.22 | |||||
| Price-to-Tangible-Book | 6.22 | |||||
| EV-to-EBIT | -22.2 | |||||
| EV-to-EBITDA | -22.7 | |||||
| EV-to-FCF | -20.6 | |||||
| Price-to-Net-Current-Asset-Value | 8.95 | |||||
| Price-to-Net-Cash | 9.14 | |||||
| Earnings Yield (Greenblatt) % | -4.5 | |||||
| FCF Yield % | -4.21 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers